Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia

Running, not enrolling · Phase 1

Conditions studied: CD 19+ Acute Leukemia

In brief

Patients with relapsed or refractory CD 19+ leukemia who have achieved remission after CD19 CAR-T cell treatment sometimes relapse because the CD 19 CAR-T cells decrease in number over time. Study PLAT-03 will test whether administering T cell antigen presenting cells (T-APCs) at intervals following treatment with CAR-T cells improves CD 19 CAR-T cell persistence and reduces the incidence of leukemia relapse.

Key facts

Study ID

NCT03186118

Run by

Seattle Children's Hospital

People needed

30

Starts

2017-08-04

Expected to finish

2033-07-01

Last updated by the study team

2026-06-05

Who can join

Age: 1 and older, up to 30. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of recurrent or refractory CD19+ leukemia
• Adequate performance status
• Able to tolerate apheresis, including placement of temporary apheresis line if required
• Adequate renal, liver, cardiac, and respiratory function
• Adequate absolute lymphocyte count
• HIV negative; Hepatitis B and C negative within 3 months prior to enrollment.

You may not qualify if…

• Evidence of active clinically significant CNS dysfunction
• Evidence of active malignancy other than CD19+ malignancy
• Evidence of active GVHD, or on immunosuppressive GVHD therapy within 4 weeks prior to enrollment

Where it is running

• Seattle Children's Hospital — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.